Bellevue Life Sciences Acquisition Corp. (BLACU) Prices $60M IPO
OSR Holdings Reg No. 589-86-01485
Email. group@osr-holdings.com
B-dong, 3F, 37-36 Hoedong-gil, Paju-si, Gyeonggi-do
Copyright © OSR Holdings.Co.,Ltd. All Rights Reserved.
OSR Holdings Co., Ltd. Reg No. 589-86-01485 Email. group@osr-holdings.com
B-dong, 3F, 37-36 Hoedong-gil, Paju-si, Gyeonggi-do
Copyright © OSR Holdings.Co.,Ltd. All Rights Reserved.
Bellevue Life Sciences Acquisition Corp. priced its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “BLACU” Friday, February 10, 2023.
The new SPAC intends to acquire a target business in the healthcare industry, specifically in the biotechnology sector developing the next generation of biologics. Bellevue Life Sciences is led by CEO Kuk Hyuon Hwang, CFO David J. Yoo, and Nominee for Chairman of the Board Steven Reed.
Total SPAC deal count for 2023 year-to-date is now 4. This offering is expected to close on Tuesday, February 14.
https://www.spacinsider.com/news/mhaddad/bellevue-life-sciences-prices-60m-ipo